© 2022 Regional Cancer Care Associates. All rights reserved.
Prospective Collection Of Donor Tissue And Blood Or Leukapheresis Product From Patients With Solid Tumours To Enable Development Of Methods For The Manufacturing Of Clonal Neoantigen T Cell Products (Cnet) Read more
A Phase 1b/2 Clinical Study Of Intratumoral Administration Of V937 In Combination With Pembrolizumab (MK-3475) In Participants With Advanced/Metastatic Solid Tumors Read more
An Open-Label, Multi-Centre Phase I/Iia Study Evaluating The Safety And Clinical Activity Of Neoantigen Reactive T Cells In Patients With Advanced Non-Small Cell Lung Cancer Read more
A Phase 1/2, Open-Label, Dose-Escalation, Safety And Tolerability Study Of NC318 In Subjects With Advanced Or Metastatic Solid Tumors Read more
Phase 1 Open-Label Study With A Novel Triple Mechanism Of Action IP In Combination With Pembrolizumab For Advanced Malignancies. Read more
A Phase 1/2, Open-Label, Dose-Escalation, Safety And Tolerability Study Of NC410 In Subjects With Advanced Or Metastatic Solid Tumors Read more
A Phase 1/2, Open-Label Study Investigating The Safety, Tolerability And Efficacy Of ASP7517 As A Single Agent And In Combination With Pembrolizumab In Patients With Advanced Solid Tumors Known To Express WT1 Antigen Read more
A Phase 1, Open-Label, Multi-Center, Dose-Finding, Pharmacokinetic, Safety And Tolerability Study Of Pf-07265807 In Participants With Selected Advanced Or Metastatic Solid Tumor Malignancies Read more
(CD47 And PD-L1) A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF PF-07257876 IN PATIENTS WITH ADVANCED OR METASTATIC TUMORS FQ Completed On: 2/4/2021 Read more
